Public procurement of medicines in Russia totaled 1 trillion rubles in 2025, representing a 26% increase compared with 2024. In physical terms, procurement volumes grew 27% year-on-year to 746 million packages. These figures were presented by Sergey Shulyak, CEO of DSM Group, at the PharmLiga forum in Moscow, GxP News reported.
Oncology drugs accounted for about one-third of total public procurement spending.
In monetary terms, government procurement increased across all programs except those implemented by the “Circle of Kindness” foundation, where spending declined slightly—from 83 billion rubles in 2024 to 80 billion rubles in 2025.
Meanwhile, pharmacy retail sales reached 2.3 trillion rubles in 2025, up 14% year-on-year. According to the expert, the share of imported medicines declined slightly—from 51.2% in 2024 to 49.6% in 2025. In physical terms, however, the share remained almost unchanged at 33.4% and 33.6%, respectively.
The total size of the Russian pharmaceutical market, including public and commercial segments as well as parapharmaceutical products, was estimated at 3.3 trillion rubles, compared with 2.6 trillion rubles a year earlier, representing 17% growth.
For 2026, Shulyak expects moderate market expansion to around 3.6 trillion rubles, driven mainly by the parapharmaceutical segment and the commercial market.
Similar to the broader retail sector, online sales are increasing in pharmaceuticals. Over the past year, the share of e-commerce grew by 1.9 percentage points to 15.9% in value terms, with 33% of online sales accounted for by dietary supplements.
Inflation in the pharmaceutical segment reached 6.7% in 2025, compared with 5.6% for overall inflation in Russia.
Source: GxP News, February 19, 2026.
